Table 1.

Common Eradication Regimens and Resistance

Therapy	Clari Susceptible	Clari Resistant	Met Resistant	Met-Clari Resistant	Levo^ Resistant	Population result^^ <90% cures**
Clari Triple 7* 93%	0-10%**	93%	0-10%**	93%		Clari >4%
Clari Triple 14 98%	0-49%**	98%	0-49%**	98%		Clari >10%
Sequential 10 94%	80%	75%	0-10%**	94%		Met and with dual resistance
Sequential 14* 98%	88%	75%	0-49%**	98%		Met and with dual resistance
Concomitant 4*	98%	97%	98%	0-49%**	98%	only with dual resistance
Levo Triple 14*	97%	97%	97%	97%	0-49%**	Levo >10%
Bismuth quad 10	93%	93%	85%	85%	93%	Met >37%
Bismuth quad 14	98%	98%	95%	95%	98%	Adherence issues primarily

^{^^}The cure rate for a population will fall below 90% when resistance exceeds the percent shown using the therapy shown.

^*7 and 10 day therapies not recommended as they either ineffective (levo) or are less effective (clari)

^**7 day 10%, 14 day 20% success with PPI + amoxicillin used for calculations when resistance was present as the represent western populations. Results depend in part of prevalence of CYP2Y19 polymorphisms as poor PPI metabolism tends to increase treatment success with this dual therapy.

^{^}Levofloxacin

Note: In the US, treatment naïve patients are expected to be resistant to clarithromycin (10%-20%) or metronidazole 20%-40%, levofloxacin (more than 30%), but not amoxicillin, tetracycline, or rifabutin <1%. Patients previously treated with macrolide, metronidazole, or quinolone are expected to have high rates of resistance, so susceptibility testing is recommended.